Melissa Bersanelli - Concepedia

Author

Melissa Bersanelli

Also Known As

Bersanelli M, Bersanelli Melissa, Carlo Genova, M Bersanelli, M. Bersanelli, MELISSA BERSANELLI, Marco Bergamini, Matthew D Hellmann, Melissa Bersanelli, S Bracarda

357

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

University of Parma Istituti di Ricovero e Cura a Carattere Scientifico University of L'Aquila San Salvatore Hospital Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

About

Melissa Bersanelli is an author at University of Parma specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	35	1.7K
2	Health Sciences	7	7	527
3	Allergy	1	1	114
4	Biostatistics	1	1	79
5	Emergency Medicine	1	1	122

Melissa Bersanelli

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Journal for ImmunoTherapy of Cancer	2019	400
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Alessio Cortellini, Sebastiano Buti, Daniele Santini, The Oncologist ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy	2019	214
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC Melissa Bersanelli, Roberta Minari, Paola Bordi, Journal of Thoracic Oncology	2016	166
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer Caroline A. Nebhan, Alessio Cortellini, Weijie Ma, JAMA Oncology	2021	146
Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients Tom van der Hulle, Paul L. den Exter, Benjamin Planquette, Journal of Thrombosis and Haemostasis ThrombosisPulmonary EmbolismVenous ThrombosisMedicineHematology	2015	122
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events Alessio Cortellini, Melissa Bersanelli, Daniele Santini, European Journal of Cancer Cancer ImmunosurveillanceMedicineBody Mass IndexImmunologyImmunoediting	2020	120
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients Giulia Mazzaschi, Roberta Minari, Alessandra Zecca, Lung Cancer Cancer ImmunosurveillanceAutoimmune DiseaseAllergySoluble Pd-l1Circulating Cd8+pd-1+	2020	114
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, European Journal of Cancer Advanced CancerMedicineImmune Checkpoint InhibitorsImmunologyPathology	2020	111
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Therapeutic Advances in Medical Oncology	2021	86

Page 1